Description

Gene therapy has a simple but serious problem: AAV vectors go where they want to go, not where you want them to go. Most love the liver. Because of this, scientists often push doses very high to force enough vector into the right tissue. That's when toxicity rises, safety drops, and manufacturing costs explode.

Now imagine you could "click" on the exact targeting protein you want, in the exact position, in the exact number of copies—turning a virus into a guided missile for one tissue. Using one ncAA (AzK) at a chosen site in the AAV capsid, this example built designer AAVs decorated with an anti-HER2 nanobody, and even with full-length trastuzumab. The standout result is the HER2-targeted vector: gene delivery to tumours jumps 19x in vivo. This lets us design vectors that hit one cell type with accuracy, reduce dose and improve safety.

Citation: Pham et al., 2025

Site-specific bioconjugation means attaching molecules at a defined position on a protein, with controlled stoichiometry. Random conjugation methods produce heterogeneous mixtures that complicate manufacturing, analytics, and regulatory filing. A genetically encoded ncAA with a click-chemistry handle addresses this by providing a single, defined attachment point.

Researchers incorporated azidolysine (AzK) at a chosen site on AAV capsid proteins, then used click chemistry to attach an anti-HER2 nanobody. The resulting targeted AAV vector achieved a 19-fold increase in gene delivery to HER2-positive tumours in vivo, compared to unmodified AAV. The same approach worked with full-length trastuzumab (Pham et al., 2025).

Site-specific ncAA conjugation applies broadly beyond gene therapy: antibody-drug conjugates, PEGylation for half-life extension, fluorescent labelling for diagnostics, and multi-domain protein assembly. The common advantage is homogeneity, where each molecule is modified at the same site in the same way, simplifying manufacturing and improving batch consistency.

Source publication